Pancreatic Cancer Research

ResearcherXianning Central HospitalActive in the last 2 years

Chao Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8452-1214; OpenAlex author ID A5100406906. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

  1. METTL3/IGF2BP3 axis promotes gemcitabine resistance of pancreatic cancer cells through regulating USP33-mediated PAK1 deubiquitination and degradation. Last author DOI 10.1007/s00210-025-04575-0↗
  2. Downregulation of long noncoding RNA SNHG14 suppresses cell proliferation and invasion by regulating EZH2 in pancreatic ductal adenocarcinoma (PDAC). Last author DOI 10.3233/cbm-190908↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ling He · 1 shared paper, 2026 · strength 0.39
  2. Xiansheng Lin · 1 shared paper, 2020 · strength 0.12
  3. Cheng Wang · 1 shared paper, 2020 · strength 0.12
  4. Fang Xie · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.